Wolfgang Willenbacher

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma

David H. Henry, Luís Costa, François Goldwasser et al. · Journal of Clinical Oncology · 2011 · 1.3K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study

Noopur Raje, Evangelos Terpos, Wolfgang Willenbacher et al. · The Lancet Oncology · 2018 · 441 citations

Medicine, Oncology, Pharmacotherapy +9

PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group

Peter Borchmann, Helen Goergen, Carsten Kobe et al. · The Lancet · 2017 · 386 citations

Medicine, Oncology, Radiation Oncology +12

Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study

Radhakrishnan Ramchandren, Eva Domingo‐Doménech, Antonio Rueda et al. · Journal of Clinical Oncology · 2019 · 256 citations · Full text

Medicine, Oncology, Pharmacology +17

Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats

Igor Theurl, Andrea Schroll, Thomas Sonnweber et al. · Blood · 2011 · 188 citations · Full text

Medicine, Pathology, Pharmacology +16